Ravidasvir

From WikiProjectMed
Jump to navigation Jump to search
Ravidasvir
Names
Other namesPPI-668
  • (2S)-2-{[Hydroxy(methoxy)methylidene]amino}-1-[(2S)-2-[5-(6-{2-[(2S)-1-[(2S)-2-{[hydroxy(methoxy)methylidene]amino}-3-methylbutanoyl]pyrrolidin-2-yl]-1H-1,3-benzodiazol-6-yl}naphthalen-2-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one
Clinical data
Drug classNS5A inhibitor[1]
Main usesHepatitis C[2]
Side effectsGenerally minor, low blood sugar[3]
Routes of
use		By mouth[2]
Chemical and physical data
FormulaC42H50N8O6
Molar mass762.912 g·mol−1
3D model (JSmol)
  • CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
  • InChI=1S/C42H50N8O6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54)/t33-,34-,35-,36-/m0/s1
  • Key:LCHMHYPWGWYXEL-ZYADHFCISA-N

Ravidasvir is a medication used to treat hepatitis C.[2] It is typically used together with sofosbuvir with a 97% cure rate.[4] It can be used in people infected with both hepatitis C and HIV/AIDS.[4] It is taken by mouth.[2]

Side effects are generally minor.[3] In people with diabetes, low blood sugar may occur.[3] In those who also have hepatitis B reactivation may occur.[3] It is a NS5A inhibitor.[1]

Ravidasvir was approved for medical use in Malaysia and Egypt in 2021.[4] It is on the World Health Organization's List of Essential Medicines.[5] A 12 week course of treatment is expected to cost about 300 to 500 USD.[1]

History

Preliminary clinical trial results were announced in Nov 2015.[6] In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt.[7] It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.[8][9]

References

  1. ↑ 1.0 1.1 1.2 "First hepatitis C treatment developed through South-South cooperation registered in Malaysia | DNDi". dndi.org. 14 June 2021. Archived from the original on 7 April 2023. Retrieved 10 September 2023.
  2. ↑ 2.0 2.1 2.2 2.3 "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Archived from the original on 10 September 2023. Retrieved 10 September 2023.
  3. ↑ 3.0 3.1 3.2 3.3 "24th WHO Expert Committee on Selection and Use of Essential Medicines Expert review" (PDF). WHO. WHO. Archived (PDF) from the original on 10 September 2023. Retrieved 10 September 2023.
  4. ↑ 4.0 4.1 4.2 "Ravidasvir + sofosbuvir | DNDi". dndi.org. 31 December 2015. Archived from the original on 21 May 2023. Retrieved 10 September 2023.
  5. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  6. ↑ "Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4". Hepatitis Magazine. November 24, 2015. Archived from the original on June 4, 2023. Retrieved August 16, 2023.
  7. ↑ Kollewe J (13 April 2018). "Non-profit's $300 hepatitis C cure as effective as $84,000 alternative". The Guardian. Archived from the original on 25 May 2023. Retrieved 16 August 2023.
  8. ↑ "List of new products approved by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia" (PDF). Archived (PDF) from the original on 2022-08-08. Retrieved 2023-08-16.
  9. ↑ "First hepatitis C treatment developed through South-South cooperation registered in Malaysia | DNDi". dndi.org. 2021-06-14. Archived from the original on 2021-08-10. Retrieved 2021-08-10.

External links

Identifiers:
Retrieved from "https://mdwiki.org/w/index.php?title=Ravidasvir&oldid=1381308"